 Hodgkin Disease
"Hodgkin Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
| Descriptor ID |
D006689
|
| MeSH Number(s) |
C04.557.386.355 C15.604.515.569.355 C20.683.515.761.355
|
| Concept/Terms |
Hodgkin Disease- Hodgkin Disease
- Disease, Hodgkin
- Granuloma, Hodgkin's
- Hodgkin's Granuloma
- Granuloma, Hodgkins
- Hodgkins Granuloma
- Lymphogranuloma, Malignant
- Lymphogranulomas, Malignant
- Malignant Lymphogranuloma
- Malignant Lymphogranulomas
- Hodgkin Lymphoma
- Lymphoma, Hodgkin
- Hodgkin's Disease
- Disease, Hodgkin's
- Hodgkin's Lymphoma
- Hodgkins Lymphoma
- Lymphoma, Hodgkin's
- Hodgkins Disease
- Disease, Hodgkins
- Granuloma, Hodgkin
- Hodgkin Granuloma
- Granuloma, Malignant
- Malignant Granuloma
- Malignant Granulomas
|
Below are MeSH descriptors whose meaning is more general than "Hodgkin Disease".
Below are MeSH descriptors whose meaning is more specific than "Hodgkin Disease".
This graph shows the total number of publications written about "Hodgkin Disease" by people in this website by year, and whether "Hodgkin Disease" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 0 | 1 | 1 | | 1993 | 1 | 0 | 1 | | 1994 | 1 | 0 | 1 | | 1995 | 2 | 0 | 2 | | 1996 | 1 | 0 | 1 | | 1997 | 2 | 1 | 3 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 3 | 0 | 3 | | 2002 | 0 | 2 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 0 | 2 | | 2005 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 1 | 3 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2014 | 2 | 0 | 2 | | 2015 | 5 | 0 | 5 | | 2016 | 10 | 0 | 10 | | 2017 | 10 | 0 | 10 | | 2018 | 10 | 0 | 10 | | 2019 | 3 | 0 | 3 | | 2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Hodgkin Disease" by people in Profiles.
-
Pinnix CC, Gunther JR, Fang P, Bankston ME, Milgrom SA, Boyce D, Lee HJ, Nair R, Steiner R, Strati P, Ahmed S, Iyer SP, Westin J, Parmar S, Rodriguez MA, Nastoupil L, Neelapu S, Flowers C, Dabaja BS. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Netw Open. 2020 09 01; 3(9):e2013935.
-
Binkley MS, Rauf MS, Milgrom SA, Pinnix CC, Tsang R, Dickinson M, Ng AK, Roberts KB, Gao S, Balogh A, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras JP, Wright C, Kelsey CR, Brady JL, Mikhaeel NG, Hoppe BS, Terezakis SA, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig JL, Jackson C, Song E, Sehgal S, Advani RH, Natkunam Y, Constine LS, Eich HT, Wirth A, Hoppe RT. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood. 2020 06 25; 135(26):2365-2374.
-
Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv. 2019 05 14; 3(9):1356-1367.
-
Bair SM, Svoboda J. Response-Adapted Treatment Strategies in Hodgkin Lymphoma Using PET Imaging. PET Clin. 2019 Jul; 14(3):353-368.
-
Milgrom SA, Elhalawani H, Lee J, Wang Q, Mohamed ASR, Dabaja BS, Pinnix CC, Gunther JR, Court L, Rao A, Fuller CD, Akhtari M, Aristophanous M, Mawlawi O, Chuang HH, Sulman EP, Lee HJ, Hagemeister FB, Oki Y, Fanale M, Smith GL. A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. Sci Rep. 2019 02 04; 9(1):1322.
-
Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. Oncologist. 2019 07; 24(7):955-962.
-
Major A, Jackson MW, Smith DE, Kamdar M, Rabinovitch R. Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis. Leuk Lymphoma. 2019 05; 60(5):1234-1243.
-
Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, Pillon M, Aladjidi N, Klingebiel T, Landman-Parker J, Medina-Sanson A, August K, Sachs J, Hoffman K, Kinley J, Song S, Song G, Zhang S, Suri A, Gore L. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018 Oct; 5(10):e450-e461.
-
Faulk KE, Sopfe JM, Campbell K, Liptzin DR, Liu AK, Franklin ARK, Cost CR. Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin. Br J Haematol. 2018 10; 183(2):251-256.
-
Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, Haverkos B. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018 07 05; 132(1):9-16.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|